Physician profile
William Wilcox
NPI 1740241470
$931.14
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $133 · 2023: $425 · 2024: $39.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $463.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $164.29 | 2021 | |
| Abbvie INC. | $81.75 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $80.81 | 2021-2023 | |
| Pfizer INC. | $74.43 | 2022-2024 | |
| Medtronic, INC. | $67.63 | 2023 | Signia |
| Glaxosmithkline, LLC. | $53.69 | 2021-2023 | Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $49.60 | 2023 | Inspire |
| Exact Sciences Corporation | $43.96 | 2023 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $42.42 | 2021-2022 | |
| Astellas Pharma US INC | $41.38 | 2023 | Veozah, Myrbetriq |
| Idorsia Pharmaceuticals US INC | $41.32 | 2023 | Quviviq |
| Novo Nordisk INC | $38.95 | 2022-2023 | Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $37.72 | 2023 | Rexulti, Abilify Maintena |
| Sumitomo Pharma America, INC. | $24.76 | 2023 | Gemtesa |
| Ultragenyx Pharmaceutical INC. | $20.93 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $20.34 | 2021 | |
| Corium, LLC | $16.33 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $15.59 | 2022 | |
| Medicure Pharma INC. | $15.24 | 2023 | Zypitamag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Wilcox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.